A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Modern management of peritoneal carcinomatosis of colorectal origin – Is hyperthermic intraoperative peritoneal chemotherapy the treatment of first choice?
Journal of Solid Tumors
Although cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is still considered as "experimental" by many, there is growing evidence that supports its general use in selective patients with peritoneal carcinomatosis of colorectal origin. The selection of patients remains challenging but is the crucial key to achieve optimal oncological results. Recent studies have shown promising results of systemic chemotherapy with biological agents in the treatment ofdoi:10.5430/jst.v4n2p1 fatcat:34czh6othjgubbkec4g2zdtl6e